SPHERE is introduced, a model-free method that makes sensitive datasets directly usable by AI and shareable for open science as a synthetic twin, while the original records never leave the local environment.
Zi-Huai He, Junyoung Park, R. C. Pulgrossi et al.· bioRxiv· 0 citations
Findings support the potential value of EOAD-signature atrophy as an MRI-based biomarker for individualized prognostication and clinical trial stratification and support the potential value of EOAD-signature atrophy as an MRI-based biomarker for individualized prognostication and clinical trial stratification.
T. Paranhos, Yuta Katsumi, M. Brickhouse et al.· Neurology· 0 citations
Routine and accessible plasma measures can be leveraged to recover reproducible, biologically distinct progression modules that improve characterization of heterogeneous AD and have practical value for risk stratification, trial enrichment, or treatment monitoring.
R. R. Butler, M. Brown, A. Weber et al.· medRxiv· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.